Knockdown of KDM4B decreases NB cell proliferation in vitro and NB xenograft growth in vivo, which provides proof-of-concept for the potential therapeutic efficacy of inhibiting KDM4B to target oncogenic MYCN signaling in cancers (73). Here, KDM4B is linked to cancer.